Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for chronic hepatitis C.
出版信息
Aust Prescr. 2016 Aug;39(4):141-143. doi: 10.18773/austprescr.2016.045. Epub 2016 May 20.
Abstract
摘要
相似文献
1
Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for chronic hepatitis C.帕利瑞韦/利托那韦/奥比他韦加达拉他韦联合利巴韦林治疗慢性丙型肝炎
Aust Prescr. 2016 Aug;39(4):141-143. doi: 10.18773/austprescr.2016.045. Epub 2016 May 20.
2
Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials.慢性丙型肝炎病毒（HCV）感染患者中，慢性肾脏病4期、终末期肾病或透析对奥比他韦、帕利瑞韦、利托那韦和达沙布韦血浆浓度的影响：3期RUBY - I和RUBY - II试验的药代动力学分析
Eur J Clin Pharmacol. 2019 Feb;75(2):207-216. doi: 10.1007/s00228-018-2566-6. Epub 2018 Oct 5.
3
Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction.使用帕利瑞韦/利托那韦/奥米他韦和达沙布韦（VIEKIRA PAK®）治疗慢性丙型肝炎继发的药物性肺炎：一例危及生命的意外不良反应病例报告
Case Rep Med. 2017;2017:4895736. doi: 10.1155/2017/4895736. Epub 2017 Mar 20.
4
Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review.用于治疗慢性丙型肝炎病毒感染的3D方案（帕利瑞韦/利托那韦-奥比他韦和达沙布韦）：简要综述
Hepat Med. 2016 May 18;8:61-8. doi: 10.2147/HMER.S72429. eCollection 2016.
5
Fatal acute liver failure during Ritonavir-boosted Paritaprevir, Ombitasvir and Dasabuvir plus Ribavirin therapy.在利托那韦增强的帕利瑞韦、奥比他韦和达沙布韦联合利巴韦林治疗期间发生的致命性急性肝衰竭。
J Gastrointestin Liver Dis. 2017 Mar;26(1):93-94. doi: 10.15403/jgld.2014.1121.261.vir.
6
Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection.维柯佳（奥比他韦、帕利瑞韦和利托那韦片；达沙布韦片）：全口服固定剂量组合药物，获批用于治疗基因1型慢性丙型肝炎感染。
Am Health Drug Benefits. 2015 Mar;8(Spec Feature):142-7.
7
Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus.奥比他韦/帕立普韦/利托那韦+达沙布韦±利巴韦林用于治疗白俄罗斯共和国慢性丙型肝炎1型。
Clin Exp Hepatol. 2017 Sep;3(3):164-168. doi: 10.5114/ceh.2017.70281. Epub 2017 Sep 25.
8
Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies.帕利瑞韦、奥比他韦、达塞布韦、利托那韦和利巴韦林治疗丙型肝炎病毒感染的肝硬化和非肝硬化患者的群体药代动力学：九项 III 期研究的分析。
Clin Pharmacokinet. 2018 Nov;57(11):1407-1419. doi: 10.1007/s40262-018-0640-y.
9
Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin.接受ombitasvir、paritaprevir/r + dasabuvir + 利巴韦林治疗的乙肝病毒合并丙肝病毒感染且伴有代偿性肝硬化患者的乙肝病毒再激活风险
J Viral Hepat. 2018 Jul;25(7):834-841. doi: 10.1111/jvh.12872. Epub 2018 Feb 21.
10
Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection.在丙型肝炎病毒感染中，使用利托那韦增强的奥比他韦/帕利瑞韦，并可能联合达沙布韦和利巴韦林的真实世界经验。
Clin Exp Hepatol. 2016 Jun;2(2):34-37. doi: 10.5114/ceh.2016.60247. Epub 2016 Jun 6.
引用本文的文献
1
Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections.丙型肝炎病毒感染的治疗/诊断方法的进展、演变和管理挑战。
Arch Virol. 2022 Mar;167(3):717-736. doi: 10.1007/s00705-022-05375-0. Epub 2022 Jan 28.
2
Sofosbuvir with velpatasvir.索磷布韦与维帕他韦联用。
Aust Prescr. 2017 Oct;40(5):200-201. doi: 10.18773/austprescr.2017.063. Epub 2017 Aug 9.
3
Elbasvir/grazoprevir.艾尔巴韦/格拉瑞韦
Aust Prescr. 2017 Feb;40(1):32-34. doi: 10.18773/austprescr.2017.010. Epub 2017 Feb 1.
本文引用的文献
1
Ledipasvir with sofosbuvir.来迪派韦与索磷布韦联用。
Aust Prescr. 2015 Dec;38(6):219-21. doi: 10.18773/austprescr.2015.078. Epub 2015 Oct 14.
2
Treating hepatitis C - what's new?治疗丙型肝炎——有哪些新进展？
Aust Prescr. 2015 Dec;38(6):191-7. doi: 10.18773/austprescr.2015.068. Epub 2015 Sep 18.
3
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.奥比他韦、帕利瑞韦与利托那韦联合达沙布韦和利巴韦林治疗 HIV-1 合并丙型肝炎病毒感染患者的随机试验。
JAMA. 2015;313(12):1223-31. doi: 10.1001/jama.2015.1328.
4
An interferon-free antiviral regimen for HCV after liver transplantation.肝移植后 HCV 的无干扰素抗病毒治疗方案。
N Engl J Med. 2014 Dec 18;371(25):2375-82. doi: 10.1056/NEJMoa1408921. Epub 2014 Nov 11.
5
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.ABT-450、利托那韦、奥比他韦和达沙布韦联合或不联合利巴韦林在治疗慢性丙型肝炎 1b 型感染的有治疗经验的患者中实现了 97%和 100%的持续病毒学应答。
Gastroenterology. 2014 Aug;147(2):359-365.e1. doi: 10.1053/j.gastro.2014.04.045. Epub 2014 May 9.
6
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.ABT-450/r-ombitasvir 和 dasabuvir 联合或不联合利巴韦林治疗 HCV。
N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4.
7
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.ABT-450/r-ombitasvir 和 dasabuvir 联合利巴韦林治疗肝硬化合并丙型肝炎。
N Engl J Med. 2014 May 22;370(21):1973-82. doi: 10.1056/NEJMoa1402869. Epub 2014 Apr 11.
8
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.ABT-450/r-ombitasvir 和利巴韦林联合治疗 HCV。
N Engl J Med. 2014 Apr 24;370(17):1594-603. doi: 10.1056/NEJMoa1315722. Epub 2014 Apr 10.
9
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.ABT-450/r-ombitasvir 和 dasabuvir 联合利巴韦林治疗 HCV。
N Engl J Med. 2014 Apr 24;370(17):1604-14. doi: 10.1056/NEJMoa1401561. Epub 2014 Apr 10.
Zotero 插件